ADMA Biologics Inc (ADMA)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 103,147 | 51,352 | 86,522 | 51,089 | 55,921 |
| Short-term investments | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 55,542 | 49,806 | 39,267 | 30,378 | 19,947 |
| Cash ratio | 1.86 | 1.03 | 2.20 | 1.68 | 2.80 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($103,147K
+ $—K)
÷ $55,542K
= 1.86
The cash ratio of ADMA Biologics Inc has fluctuated over the past five years. As of December 31, 2020, the cash ratio stood at a healthy level of 2.80, indicating that the company had $2.80 in cash and cash equivalents for every $1 of current liabilities. However, by December 31, 2023, the cash ratio had decreased significantly to 1.03, which may suggest a potential liquidity concern as the company had only $1.03 in cash for every $1 of current liabilities.
Subsequently, the cash ratio improved to 1.86 as of December 31, 2024, but it still lags behind the level seen in 2020. Overall, while the company has experienced fluctuations in its cash ratio, it is essential for investors and stakeholders to closely monitor this metric to assess ADMA Biologics Inc's liquidity position and ability to meet its short-term obligations.
Peer comparison
Dec 31, 2024